Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Breast Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 24 articles: HTML format

Single Articles

October 2022
1. CORTES J, Zhou X, Schmid P
   Pembrolizumab in Triple-Negative Breast Cancer. Reply.
   N Engl J Med. 2022;387:1436.
   PubMed    
   
   
   
2. ALTUNDAG K
   Pembrolizumab in Triple-Negative Breast Cancer.
   N Engl J Med. 2022;387:1435-1436.
   PubMed    
   
   
   
3. SUN R, Wei LJ
   Pembrolizumab in Triple-Negative Breast Cancer.
   N Engl J Med. 2022;387:1435.
   PubMed    
   
   
   September 2022
4. MODI S, Gambhire D, Cameron D
   Trastuzumab Deruxtecan in HER2-Low Breast Cancer. Reply.
   N Engl J Med. 2022;387:1145-1146.
   PubMed    
   
   
   
5. CARROLL HK, Higgins MJ, O'Reilly S
   Trastuzumab Deruxtecan in HER2-Low Breast Cancer.
   N Engl J Med. 2022;387:1144.
   PubMed    
   
   
   
6. SCHNOG JB, Samson MJ, Duits AJ
   Trastuzumab Deruxtecan in HER2-Low Breast Cancer.
   N Engl J Med. 2022;387:1143-1144.
   PubMed    
   
   
   August 2022
7. CHRISTIAN NT, Borges VF
   What Dobbs Means for Patients with Breast Cancer.
   N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMp2209249.
   PubMed    
   
   
   July 2022
8. PIVOT X
   Pembrolizumab in the Treatment of Breast Cancer.
   N Engl J Med. 2022;387:273-274.
   PubMed    
   
   
   
9. CORTES J, Rugo HS, Cescon DW, Im SA, et al
   Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
   N Engl J Med. 2022;387:217-226.
   PubMed     Abstract available
   
   
   
10. HURVITZ SA
    DESTINY-Changing Results for Advanced Breast Cancer.
    N Engl J Med. 2022;387:75-76.
    PubMed    
    
    
    June 2022
11. JATOI I, Sung H, Jemal A
    The Emergence of the Racial Disparity in U.S. Breast-Cancer Mortality.
    N Engl J Med. 2022;386:2349-2352.
    PubMed    
    
    
    
12. CORTES J, Im SA, Cathcart J
    Trastuzumab Deruxtecan for Breast Cancer. Reply.
    N Engl J Med. 2022;386:2347.
    PubMed    
    
    
    
13. ZHENG F, Du F, Yuan P
    Trastuzumab Deruxtecan for Breast Cancer.
    N Engl J Med. 2022;386:2346-2347.
    PubMed    
    
    
    
14. MODI S, Jacot W, Yamashita T, Sohn J, et al
    Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
    N Engl J Med. 2022 Jun 5. doi: 10.1056/NEJMoa2203690.
    PubMed     Abstract available
    
    
    May 2022
15. SCHMID P, Cortes J, Dent R
    Pembrolizumab in Early Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2022;386:1771-1772.
    PubMed    
    
    
    
16. GANGULY S, Gogia A
    Pembrolizumab in Early Triple-Negative Breast Cancer.
    N Engl J Med. 2022;386:1771.
    PubMed    
    
    
    March 2022
17. CORTES J, Kim SB, Chung WP, Im SA, et al
    Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    N Engl J Med. 2022;386:1143-1154.
    PubMed     Abstract available
    
    
    
18. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
    N Engl J Med. 2022;386:942-950.
    PubMed     Abstract available
    
    
    February 2022
19. SCHMID P, Cortes J, Dent R, Pusztai L, et al
    Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
    N Engl J Med. 2022;386:556-567.
    PubMed     Abstract available
    
    
    December 2021
20. SHARMA V, Kumar A
    Carcinoma en Cuirasse.
    N Engl J Med. 2021;385:2562.
    PubMed    
    
    
    
21. KALINSKY K, Barlow WE, Gralow JR, Meric-Bernstam F, et al
    21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
    N Engl J Med. 2021;385:2336-2347.
    PubMed     Abstract available
    
    
    October 2021
22. TUTT ANJ, Garber JE, Geyer CE Jr
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply.
    N Engl J Med. 2021;385:1440.
    PubMed    
    
    
    
23. HOSHI A, Bando H, Sekine I
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439-1440.
    PubMed    
    
    
    
24. NOZAWA K, Yoshimura A, Iwata H
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: